Automated Lugano Metabolic Response Assessment in F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on F-Fluorodeoxyglucose-Positron Emission Tomography.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PMID:

Abstract

PURPOSE: Artificial intelligence can reduce the time used by physicians on radiological assessments. For F-fluorodeoxyglucose-avid lymphomas, obtaining complete metabolic response (CMR) by end of treatment is prognostic.

Authors

  • Skander Jemaa
    Genentech, Inc., South San Francisco, CA, USA.
  • Souhila Ounadjela
    Genentech, Inc, South San Francisco, CA.
  • Xiaoyong Wang
    Genentech, Inc., South San Francisco, CA, USA. wang.xiaoyong@gene.com.
  • Tarec C El-Galaly
    Jorne L. Biccler, Lasse Hjort Jakobsen, Martin Bøgsted, and Tarec C. El-Galaly, Aalborg University Hospital and Aalborg University, Aalborg; Peter de Nully Brown, Copenhagen University Hospital, Copenhagen; Henrik Frederiksen, Odense University Hospital, Odense; Judit Jørgensen, Aarhus University Hospital, Aarhus; Denmark; Sandra Eloranta and Karin E. Smedby, Karolinska Institutet, Stockholm; Mats Jerkeman, Lund University, Lund; and Karin E. Smedby, Karolinska University Hospital, Solna, Sweden.
  • Lale Kostakoglu
    Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, United States of America.
  • Andrea Knapp
    F Hoffmann-La Roche, Basel, Switzerland.
  • Grace Ku
    Genentech, Inc, South San Francisco, CA.
  • Lisa Musick
    Genentech, Inc, South San Francisco, CA.
  • Denis Sahin
    F Hoffmann-La Roche, Basel, Switzerland.
  • Michael C Wei
    Genentech, Inc, South San Francisco, CA.
  • Shen Yin
    Department of Mechanical and Industrial Engineering, Faculty of Engineering, Norwegian University of Science and Technology, Trondheim, Norway.
  • Thomas Bengtsson
    Genentech, Inc., South San Francisco, CA, USA.
  • Alex de Crespigny
    From the Department of Product Development-Personalized HealthCare Imaging (A.P.K., Z.S., T.B., R.A.D.C.), Clinical Imaging Group, gRED (D.C., A.d.C.), and DevSci OMNI-Biomarker Development (X.J.), Genentech, 600 E Grand Ave, South San Francisco, CA 94080; and Global Product Development Medical Affairs, Neuroscience, F. Hoffmann-La Roche, Basel, Switzerland (L.G.).
  • Richard A D Carano
    From the Department of Product Development-Personalized HealthCare Imaging (A.P.K., Z.S., T.B., R.A.D.C.), Clinical Imaging Group, gRED (D.C., A.d.C.), and DevSci OMNI-Biomarker Development (X.J.), Genentech, 600 E Grand Ave, South San Francisco, CA 94080; and Global Product Development Medical Affairs, Neuroscience, F. Hoffmann-La Roche, Basel, Switzerland (L.G.).